If a drug passes safety in early testing, what is the likely main focus of subsequent trials?

If a drug passes safety in early testing, what is the likely main focus of subsequent trials?

• A. Evaluate marketing potential
• B. Prove the drug works in humans
• C. Determine the optimum dosage
• D. Assess environmental impact

Answer: (C)

When safety is established in early testing, the next trials focus on finding the right dose that provides the best balance of benefit and risk. This means dose-ranging studies to see how different amounts affect efficacy and side effects, so you can identify the optimal dosage and dosing schedule. This dose-optimization work lays the groundwork for larger trials that confirm efficacy at that chosen dose. Marketing potential isn’t evaluated in these early phases, and environmental impact isn’t part of the clinical trial goals. While proving the drug can work in humans is part of the overall process, the primary aim now is to pinpoint the best dose.

When safety is established in early testing, the next trials focus on finding the right dose that provides the best balance of benefit and risk. This means dose-ranging studies to see how different amounts affect efficacy and side effects, so you can identify the optimal dosage and dosing schedule. This dose-optimization work lays the groundwork for larger trials that confirm efficacy at that chosen dose. Marketing potential isn’t evaluated in these early phases, and environmental impact isn’t part of the clinical trial goals. While proving the drug can work in humans is part of the overall process, the primary aim now is to pinpoint the best dose.